Apogee Therapeutics Inc
NASDAQ:APGE
Cash Flow Statement
Cash Flow Statement
Apogee Therapeutics Inc
| Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||
| Net Income |
(67)
|
(88)
|
(84)
|
(104)
|
(118)
|
(147)
|
(182)
|
(205)
|
(238)
|
(254)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Stock-Based Compensation |
5
|
6
|
6
|
9
|
14
|
18
|
23
|
30
|
36
|
42
|
|
| Other Non-Cash Items |
14
|
16
|
3
|
4
|
5
|
7
|
13
|
21
|
28
|
37
|
|
| Change in Working Capital |
11
|
11
|
6
|
4
|
2
|
6
|
(2)
|
(4)
|
(12)
|
(17)
|
|
| Cash from Operating Activities |
(42)
N/A
|
(61)
-48%
|
(75)
-22%
|
(96)
-28%
|
(111)
-15%
|
(133)
-20%
|
(171)
-28%
|
(188)
-10%
|
(221)
-17%
|
(232)
-5%
|
|
| Investing Cash Flow | |||||||||||
| Capital Expenditures |
0
|
0
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(5)
|
(6)
|
(5)
|
|
| Other Items |
0
|
(234)
|
(274)
|
(325)
|
(474)
|
(385)
|
(299)
|
(231)
|
(3)
|
161
|
|
| Cash from Investing Activities |
0
N/A
|
(234)
N/A
|
(274)
-17%
|
(326)
-19%
|
(474)
-46%
|
(387)
+19%
|
(300)
+22%
|
(236)
+22%
|
(9)
+96%
|
155
N/A
|
|
| Financing Cash Flow | |||||||||||
| Net Issuance of Common Stock |
163
|
479
|
315
|
766
|
766
|
451
|
495
|
45
|
47
|
66
|
|
| Other |
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Financing Activities |
162
N/A
|
479
+196%
|
315
-34%
|
766
+143%
|
767
+0%
|
451
-41%
|
495
+10%
|
45
-91%
|
47
+3%
|
66
+42%
|
|
| Change in Cash | |||||||||||
| Net Change in Cash |
120
N/A
|
183
+53%
|
(33)
N/A
|
344
N/A
|
183
-47%
|
(69)
N/A
|
23
N/A
|
(379)
N/A
|
(183)
+52%
|
(11)
+94%
|
|
| Free Cash Flow | |||||||||||
| Free Cash Flow |
(42)
N/A
|
(61)
-48%
|
(75)
-22%
|
(96)
-29%
|
(111)
-15%
|
(135)
-21%
|
(172)
-28%
|
(193)
-12%
|
(227)
-17%
|
(238)
-5%
|
|